TacticScaleWhat DaShenLin Pharmaceutical (大参林) Does & How It Makes Money (603233.SS)
Updated October 2026 · reflects DaShenLin Pharmaceutical's latest reported financials
Chinese pharmacy chain that also makes and distributes medicines. It makes most of its money selling medicines and health products to consumers through its pharmacies.
How DaShenLin Pharmaceutical makes money
It makes most of its money selling medicines and health products to consumers through its pharmacies. Manufacturing and wholesale distribution of pharmaceutical products bring in additional revenue.
What DaShenLin Pharmaceutical does
DaShenLin Pharmaceutical Group is a Guangzhou-based healthcare company founded in 1999. Its main business is pharmaceutical retail in China, and it also manufactures and distributes medicines. The product range covers both Western drugs and traditional Chinese medicine. The company sells Chinese and Western patent medicines, ginseng and tonic herbs, Chinese herbal medicine slices, health products and medical devices. Because it sells both modern pharmaceuticals and TCM products, it serves everyday healthcare and wellness spending by Chinese consumers.
Products & services
- Chinese and Western patent medicines
- Ginseng and tonic herbs
- Chinese herbal medicine slices
- Health products
- Medical devices
大参林是做什么的？
大参林医药集团股份有限公司成立于1999年，总部位于广州，主要在中国从事医药零售，同时经营药品的生产和批发分销。 公司销售中成药、西药、人参滋补品、中药饮片、保健品和医疗器械等商品。它既卖现代药品，也卖传统中医药产品，满足中国消费者的日常医疗和保健需求。
What is DaShenLin Pharmaceutical worth?
On an owner-earnings DCF, DaShenLin Pharmaceutical's most-likely value is about ¥63 versus a recent price near ¥19 (69% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~¥25) with a margin of safety — so the honest verdict here is “Deeply discounted.” Fair value earns its keep only at the extremes, not in the wide middle.
On the financials alone, $19 is below even the no-growth floor ($25); the market's discount — expectations and sentiment beyond the numbers — is pricing in ≈ -2.7%/yr. A bargain only if that pessimism is overdone.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Shanghai Pharmaceuticals Holding (601607.SS) · China National Accord Medicines (000028.SZ) · Tianjin Pharmaceutical Da Ren Tang (600329.SS) · LBX Pharmacy Chain Joint Stock (603883.SS)